Abstract:Ethnopharmacological relevance Ginsenoside Rg1 (Rg1) is one of the main active components in Panax ginseng C. A. Meyer (ginseng), which has been widely used to delay senescence or improve health conditions for more than 2000 years. Increasing studies have revealed that Rg1 could regulate cell proliferation and differentiation, as well as anti-inflammatory and anti-apoptotic effects, and might have protective effects on many chronic kidney diseases. Aim of the study Diabetic nephropathy (DN) is one of the most dangerous microvascular complications of diabetes and is the leading cause of end-stage renal disease worldwide. However, the role and mechanism of Rg1 against high-glucose and high-fat-induced glomerular fibrosis in DN are not clear. This study aimed to investigate the protective effect of Rg1 on DN and its possible mechanism. Materials and methods The type 2 diabetes mellitus (T2DM) mice models were established with a high-fat diet (HFD) combined with an intraperitoneal injection of streptozotocin (STZ). Urine protein and serum biochemical indexes were detected by corresponding kits. The kidney was stained with H&E, PAS, and Masson to observe the pathological morphology, glycogen deposition, and fibrosis. The expression of CD36 and p-PLC in the kidney cortex was detected by IHC. The expressions of FN and COL4 were detected by IF. Western blot and PCR were performed to examine protein and mRNA expressions of kidney fibrosis and TRPC6/NFAT2-related pathways in DN mice. Calcium imaging was used to examine the effect of Rg1 on [Ca 2+ ] i in PA + HG-induced human mesangial cells (HMCs). Visualization of the interaction between Rg1 and CD36 was detected by molecular docking. Results Rg1 treatment for 8 weeks could prominently decrease urinary protein, serum creatinine, and urea nitrogen and downgrade blood lipid levels and renal lipid accumulation in T2DM mice. The pathological results indicated that Rg1 treatment attenuated renal pathological injury and glomerular fibrosis. The further results demonstrated that Rg1 treatment remarkably decreased the expressions of CD36, TRPC6, p-PLC, CN, NFAT2, TGF-β, p-Smad2/3, COL4, and FN in renal tissues from T2DM mice. Calcium imaging results found that Rg1 downgraded the base levels of [Ca 2+ ] i and ΔRatioF340/F380 after BAPTA and CaCl 2 treatment. Molecular docking results showed that Rg1 could interact with CD36 with a good affinity. Conclusion These results revealed that Rg1 could ameliorate renal lipid accumulation, pathological damage, and glomerular fibrosis in T2DM mice. The mechanism may be involved in reducing the overexpression of CD36 and inhibiting the TRPC6/NFAT2 signaling pathway in renal tissues of T2DM mice.

Ginsenoside Rg1 Alleviates Podocyte Injury Induced by Hyperlipidemia Via Targeting the Mtor/nf-Κb/nlrp3 Axis.

Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.

Ginsenoside Rg1 Alleviates Podocyte EMT Passage by Regulating AKT/GSK3 Β/β-Catenin Pathway by Restoring Autophagic Activity

Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.

Ginsenoside Rg1 attenuates the inflammation and oxidative stress induced by diabetic nephropathy through regulating the PI3K/AKT/FOXO3 pathway

Notoginsenoside R1 Attenuates Glucose-Induced Podocyte Injury Via the Inhibition of Apoptosis and the Activation of Autophagy Through the Pi3k/Akt/Mtor Signaling Pathway

Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity

Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo.

Ginsenoside-Rg1 Protects Podocytes from Complement Mediated Injury

Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice

Ginsenoside Rg1 Alleviates Diabetic Liver Injury and Fibrosis by Inhibiting the PLC-NFAT2-NLRP3 Signaling Pathway in T2DM Mice

Protective Effect of Ginsenoside Rg5 Against Kidney Injury Via Inhibition of NLRP3 Inflammasome Activation and the MAPK Signaling Pathway in High-Fat Diet/streptozotocin-Induced Diabetic Mice.

Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway

Ginsenoside Rg1 Inhibits Angiotensin Ii-Induced Podocyte Autophagy Via Ampk/Mtor/Pi3k Pathway

Ginsenoside Rg1 Ameliorates Pancreatic Injuries Via the AMPK/mTOR Pathway in Vivo and in Vitro.

Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy

Ginsenoside Rg1 protects mouse podocytes from aldosterone-induced injury in vitro

Notoginsenoside R1 can inhibit the interaction between FGF1 and VEGFA to retard podocyte apoptosis

Ginsenoside Rh1 Improves Type 2 Diabetic Nephropathy Through AMPK/PI3K/Akt-Mediated Inflammation and Apoptosis Signaling Pathway.

GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway